LUCY DELANEY CARTER REARDON
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner|Family KANSAS CITY, MO NPI 1669902706
Browse related groups: Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner|Family MO Novo Nordisk AS All categories
General Payments — all program years on this page
$24,646.33
- Category: General Payments
- Program years: PY2022–2024
- Record count: 49
- As of (CMS publication): 2026-01-23
Latest program year (PY2024): $6,242.81 across 8 records · disputed records: 0
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How this figure is calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
Latest program year (PY2024) · sorted by reported total.
| Nature of payment | Amount | Records |
|---|---|---|
| Consulting Fee | $4,468.75 | 2 |
| Travel and Lodging | $1,335.91 | 3 |
| Food and Beverage | $438.15 | 3 |
By paying entity
Latest program year (PY2024) · sorted by reported total.
| Paying entity | Amount | Records |
|---|---|---|
| Novo Nordisk AS | $5,033.85 | 6 |
| Takeda Pharmaceuticals U.S.A., Inc. | $1,090.00 | 1 |
| GENZYME CORPORATION | $118.96 | 1 |
By program year
Records — PY2024 (8)
| Record ID | Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Source |
|---|---|---|---|---|---|---|---|
| 1100257380 | Novo Nordisk Inc | $451.53 | 10/04/2024 | Travel and Lodging | Undisputed | 01/23/2026 | View at CMS |
| 1100335226 | Novo Nordisk Inc | $7.20 | 04/04/2024 | Food and Beverage | Undisputed | 01/23/2026 | View at CMS |
| 1100501443 | Novo Nordisk Inc | $418.04 | 10/04/2024 | Travel and Lodging | Undisputed | 01/23/2026 | View at CMS |
| 1100658076 | Novo Nordisk Inc | $3,378.75 | 10/04/2024 | Consulting Fee | Undisputed | 01/23/2026 | View at CMS |
| 1100658290 | Novo Nordisk Inc | $311.99 | 10/04/2024 | Food and Beverage | Undisputed | 01/23/2026 | View at CMS |
| 1100658332 | Novo Nordisk Inc | $466.34 | 10/04/2024 | Travel and Lodging | Undisputed | 01/23/2026 | View at CMS |
| 1137723326 | Takeda Pharmaceuticals U.S.A., Inc. | $1,090.00 | 02/27/2024 | Consulting Fee | Undisputed | 01/23/2026 | View at CMS |
| 1139926563 | GENZYME CORPORATION | $118.96 | 04/03/2024 | Food and Beverage | Undisputed | 01/23/2026 | View at CMS |
Provenance & corrections
- Dataset: CMS Open Payments — General Payments
- Source: CMS Open Payments dataset (bulk file)
- Publisher of source data: Centers for Medicare & Medicaid Services
- Generated from: OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.